Anders Svenningsson - Department of Clinical Chemistry, University of Gothenburg

基本信息

浏览量：62

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 193 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Comparison of CSF Biomarkers in Multiple Sclerosis Patients Treated with Natalizumab and Rituximab

Johan Hellgren, Isabella Ahlström, Maria Compagno Strandberg, Magnus Förnvik Jonsson,Oskar Hansson,Shorena Janelidze,Anders Svenningsson, Kristina Källén

Multiple sclerosis and related disorders (2025): 106479-106479

引用0浏览0WOS引用

Clinical Effectiveness and Safety of Cladribine Tablets for Patients Treated at Least 24 Months in the Swedish Post-Market Surveillance Study "immunomodulation and Multiple Sclerosis Epidemiology 10"(IMSE 10)

Veronica Larsson,Linda Forsberg,Jan Hillert,Petra Nilsson,Charlotte Dahle,Anders Svenningsson,Jan Lycke,Anne-Marie Landtblom,Joachim Burman,Claes Martin,Peter Sundstrom,Martin Gunnarsson,Fredrik Piehl,Tomas Olsson

MULTIPLE SCLEROSIS JOURNALno. 3 (2024): 665-666

引用0浏览0引用

A Comparison of Administration and Discontinuation of Natalizumab in Sweden over Time for Patients Treated with Either Subcutaneous (SC) or Intravenous (IV) Administration Methods Since July 2021

Linda Forsberg,Veronica Larsson,Jan Hillert,Petra Nilsson,Charlotte Dahle,Anders Svenningsson,Jan Lycke,Anne-Marie Landtblom,Joachim Burman,Peter Sundstrom,Claes Martin,Martin Gunnarsson,Fredrik Piehl,Tomas Olsson

MULTIPLE SCLEROSIS JOURNALno. 3 (2024): 1069-1070

引用0浏览0引用

A Comparative Study of Fatigue and Processing Speed in Patients with Multiple Sclerosis Treated with Natalizumab or Rituximab

Johan Hellgren,Maria Compagno Strandberg,Kristina Kallen,Anders Svenningsson

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICALno. 2 (2024)

引用0浏览0WOS引用

Clinical Effectiveness and Safety of Ofatumumab for Patients Treated Since March 2021 in the Swedish Post-Market Surveillance Study "immunomodulation and Multiple Sclerosis Epidemiology 12" (IMSE 12)

MULTIPLE SCLEROSIS JOURNALno. 3 (2024): 1072-1073

引用0浏览0引用

Prescription of Antibiotics in Patients with Multiple Sclerosis Treated with Rituximab: a 10-Year Retrospective Cohort Study

Niclas Lange,Martin Gunnarsson,Elisabet Tina,Olof Hultgren,Anders Svenningsson

MULTIPLE SCLEROSIS JOURNALno. 3 (2024): 484-484

引用0浏览0引用

COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab

Fredrik Piehl,Peter Alping, Suvi Virtanen,Simon Englund,Joachim Burman,Katharina Fink,Anna Fogdell-Hahn,Martin Gunnarsson,Jan Hillert,Annette Langer Gould,Jan Lycke,Johan Mellergard,Petra Nilsson,Tomas Olsson,Jonatan Salzer,Anders Svenningsson,Thomas Frisell

MULTIPLE SCLEROSIS JOURNALno. 3 (2024): 87-88

引用1浏览0WOS引用

Clinical Effectiveness of Cladribine Tablets for Patients below or above 45 Years of Age at Treatment Start in the Swedish Post-Market Surveillance Study "immunomodulation and Multiple Sclerosis Epidemiology 10" (IMSE 10)

MULTIPLE SCLEROSIS JOURNALno. 3 (2024): 658-659

引用0浏览0引用

Clinical Effectiveness and Safety of Dimethyl Fumarate for Patients Treated at Least 6 Years in the Swedish Post-Market Surveillance Study "immunomodulation and Multiple Sclerosis Epidemiology 5" (IMSE 5)

Linda Forsberg,Veronica Larsson,Jan Hillert,Petra Nilsson,Charlotte Dahle,Anders Svenningsson,Jan Lycke,Anne-Marie Landtblom,Joachim Burman,Claes Martin,Peter Sundstrom,Martin Gunnarsson,Fredrik Piehl,Tomas Olsson

MULTIPLE SCLEROSIS JOURNAL（2024）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn